- Home
- RLAY vs AIO Comparison
RLAY vs AIO Comparison
Compare RLAY & AIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLAY
- AIO
- Stock Information
- Founded
- RLAY 2015
- AIO 2019
- Country
- RLAY United States
- AIO United States
- Employees
- RLAY N/A
- AIO N/A
- Industry
- RLAY Biotechnology: Biological Products (No Diagnostic Substances)
- AIO Finance/Investors Services
- Sector
- RLAY Health Care
- AIO Finance
- Exchange
- RLAY Nasdaq
- AIO Nasdaq
- Market Cap
- RLAY 803.4M
- AIO 808.3M
- IPO Year
- RLAY 2020
- AIO N/A
- Fundamental
- Price
- RLAY $6.72
- AIO $24.35
- Analyst Decision
- RLAY Strong Buy
- AIO
- Analyst Count
- RLAY 8
- AIO 0
- Target Price
- RLAY $17.25
- AIO N/A
- AVG Volume (30 Days)
- RLAY 2.0M
- AIO 141.5K
- Earning Date
- RLAY 11-06-2025
- AIO 01-01-0001
- Dividend Yield
- RLAY N/A
- AIO 9.05%
- EPS Growth
- RLAY N/A
- AIO N/A
- EPS
- RLAY N/A
- AIO N/A
- Revenue
- RLAY $8,355,000.00
- AIO N/A
- Revenue This Year
- RLAY $27.30
- AIO N/A
- Revenue Next Year
- RLAY $7.43
- AIO N/A
- P/E Ratio
- RLAY N/A
- AIO N/A
- Revenue Growth
- RLAY N/A
- AIO N/A
- 52 Week Low
- RLAY $1.78
- AIO $15.09
- 52 Week High
- RLAY $7.64
- AIO $20.25
- Technical
- Relative Strength Index (RSI)
- RLAY 55.13
- AIO 54.43
- Support Level
- RLAY $6.64
- AIO $24.10
- Resistance Level
- RLAY $7.42
- AIO $24.78
- Average True Range (ATR)
- RLAY 0.43
- AIO 0.35
- MACD
- RLAY -0.11
- AIO 0.09
- Stochastic Oscillator
- RLAY 30.97
- AIO 75.23
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
About AIO Virtus Artificial Intelligence & Technology Opportunities Fund of Beneficial Interest
Virtus Artificial Intelligence & Technology Opportunities Fund is a diversified, limited-term, closed-end management investment company. The fund's investment objective is to provide total return through a combination of current income, current gains, and long-term capital appreciation.